Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

Anita Turk, MD, discusses the unmet needs that still exist in the realm of colorectal cancer treatment and management.

The growing prevalence of chronic diseases is a major factor driving revenue growth in the natural killer (NK) cell ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful ...

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative ...

Sarcoma Awareness Month sheds light on rare cancers, emphasizing early detection, research advancement, and patient support.

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...